Liver (Hepatocellular) Cancer Screening (PDQ®)—Health Professional Version - National Cancer Institute

Liver (Hepatocellular) Cancer Screening (PDQ®)—Health Professional Version - National Cancer Institute

Liver (Hepatocellular) Cancer Screening (PDQ®)–Health Professional Version

Go to Patient Version

LIVER & BILE DUCT CANCER

• Patient
• Health Professional
  • Adult Liver Cancer Treatment
  • Bile Duct Cancer (Cholangiocarcinoma) Treatment
  • Childhood Liver Cancer Treatment
  • Liver Cancer Prevention
  • Liver Cancer Screening
• Research

SECTIONS

• Summary of Evidence
• Significance
• Evidence of Benefit
• Evidence of Harms
• Changes to This Summary (04/​12/​2018)
• About This PDQ Summary
• View All Sections

Summary of Evidence

• Benefits
• Harms

Note: Separate PDQ summaries on Adult Primary Liver Cancer Treatment and Childhood Liver Cancer Treatment are also available.

Benefits

Based on fair evidence, screening of persons at elevated risk does not result in a decrease in mortality from hepatocellular cancer.

Magnitude of Effect: No reduction in mortality.

• Study Design: Randomized controlled trials.
• Internal Validity: Fair.
• Consistency: Multiple studies, large number of participants.
• External Validity: Fair.

Harms

Based on fair evidence, screening would result in rare but serious side effects associated with needle aspiration cytology such as needle-track seeding, particularly of lesions more than 2 cm in diameter, and hemorrhage, bile peritonitis, and pneumothorax. Transjugular liver biopsy is rarely associated with major complications such as perforation of the hepatic capsule or cholangitis.

Magnitude of Effect: Good evidence for uncommon but serious harms.

• Study Design: Randomized controlled trials and observational studies.
• Internal Validity: Fair.
• Consistency: Multiple studies, large number of participants.
• External Validity: Good.

Next section >
Significance